Penumbra Inc
NYSE:PEN

Watchlist Manager
Penumbra Inc Logo
Penumbra Inc
NYSE:PEN
Watchlist
Price: 244.84 USD 1.81% Market Closed
Market Cap: 9.4B USD
Have any thoughts about
Penumbra Inc?
Write Note

Penumbra Inc
Accrued Liabilities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Penumbra Inc
Accrued Liabilities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Accrued Liabilities CAGR 3Y CAGR 5Y CAGR 10Y
Penumbra Inc
NYSE:PEN
Accrued Liabilities
$116.4m
CAGR 3-Years
7%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Becton Dickinson and Co
NYSE:BDX
Accrued Liabilities
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Boston Scientific Corp
NYSE:BSX
Accrued Liabilities
$2.3B
CAGR 3-Years
4%
CAGR 5-Years
7%
CAGR 10-Years
7%
Stryker Corp
NYSE:SYK
Accrued Liabilities
$3.5B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
3%
Abbott Laboratories
NYSE:ABT
Accrued Liabilities
$6.5B
CAGR 3-Years
-1%
CAGR 5-Years
4%
CAGR 10-Years
6%
Intuitive Surgical Inc
NASDAQ:ISRG
Accrued Liabilities
$867.5m
CAGR 3-Years
21%
CAGR 5-Years
13%
CAGR 10-Years
15%
No Stocks Found

Penumbra Inc
Glance View

Market Cap
9.4B USD
Industry
Health Care

Penumbra Inc. is revolutionizing the landscape of medical technology with its innovative solutions tailored to treat some of the most challenging conditions in neuro and peripheral vascular health. Founded in 2004, the company has swiftly positioned itself as a leader in developing devices that empower physicians to provide advanced, minimally invasive treatment options. Penumbra's flagship products, including the Penumbra System for thrombectomy and its suite of neurovascular devices, showcase its commitment to enhancing patient outcomes and streamlining procedures. With a strong focus on research and development, the company aims to address unmet medical needs, thus facilitating its growth trajectory in a market with substantial demand. As an investment opportunity, Penumbra Inc. stands out not only for its robust pipeline of innovative technologies but also for its impressive financial performance. The company has demonstrated strong revenue growth driven by increasing market adoption of its products and strategic expansions into new therapeutic areas. With healthcare's ongoing shift toward minimally invasive treatments, Penumbra is ideally positioned to capitalize on this trend, supported by a team of experienced professionals and a culture of innovation. For investors, Penumbra offers a compelling blend of growth prospects and the potential for long-term returns as it continues to redefine standards of care in the medical device industry.

PEN Intrinsic Value
106.95 USD
Overvaluation 56%
Intrinsic Value
Price

See Also

What is Penumbra Inc's Accrued Liabilities?
Accrued Liabilities
116.4m USD

Based on the financial report for Sep 30, 2024, Penumbra Inc's Accrued Liabilities amounts to 116.4m USD.

What is Penumbra Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
12%

Over the last year, the Accrued Liabilities growth was 9%. The average annual Accrued Liabilities growth rates for Penumbra Inc have been 7% over the past three years , 12% over the past five years .

Back to Top